Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Soaring oil prices tear apart the policy balance: Bank of Japan faces a life-or-death dilemma between raising interest rates and maintaining stability

Soaring oil prices tear apart the policy balance: Bank of Japan faces a life-or-death dilemma between raising interest rates and maintaining stability

汇通财经汇通财经2026/03/16 07:10
Show original
1. The Iran conflict has pushed up crude oil prices, putting the Bank of Japan in a dilemma once again: should it pause rate hikes to consider political and economic growth, or continue raising rates to curb inflation and support the yen? On one hand, soaring energy prices drive up overall inflation, providing justification for rate hikes; on the other hand, they may hit consumer spending and further burden already struggling small and medium-sized enterprises.2. The current situation is reminiscent of the aftermath of the Russia-Ukraine conflict. However, policymakers say the background in Japan is different this time: inflation expectations are finally starting to form, and the underlying price increase is approaching the 2% target, meaning the central bank may not have much time left to carefully consider its next move. According to insiders, despite geopolitical turmoil, officials remain committed to seeking rate hikes, but it will be difficult to act at this week's meeting.3. The market bets that the probability of the Bank of Japan raising rates this week is almost zero, with expectations for an April hike at about 60%. At that time, the central bank will release its latest economic forecasts. Daiwa Securities economists warn that if oil prices remain high, there is a risk of a vicious cycle: worsening trade deficits lead to a weaker yen, further increases in import prices, and inflationary pressures accumulate beneath the surface.4. Another complicating factor is Prime Minister Sanae Takaichi's policy inclination. She focuses on economic growth and tends to favor a loose financial environment to ease supply shocks. The government is cushioning the economic impact through gasoline subsidies and releasing reserves, but the persistent weakness of the yen poses a systemic challenge. The central bank governor has acknowledged that exchange rate fluctuations now more easily affect domestic prices.5. Economists expect the Bank of Japan to wait until April to raise rates, but the pace of tightening may be slower than what economic fundamentals require. "Whether the Bank of Japan can raise rates in April will be a turning point in determining market confidence in its continued tightening strategy."
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

US Stock Movement | SuperX AI Technology (SUPX.US) once fell more than 2.5%, hitting an intraday low of $6.46

SuperX AI Technology's stock price declined, falling more than 2.5% at one point.

智通财经•2026/10/08 16:11

BUZZ-Pacira BioSciences participated in a Viatris acquisition deal worth 1.65 billions dollars

Latest Update October 8 – Pacira BioSciences (PCRX.O) shares surged by 44%, hitting a more than three-year high at $36.30. If the rally holds, PCRX is poised for its largest single-day gain on record. Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences in a $1.65 billion cash deal, offering $36.50 per share. The offer represents a premium of approximately 44.8% over Pacira’s recent closing price of $25.20. The transaction will add Pacira’s non-opioid pain medications Exparel and Zilretta to Viatris' product portfolio. Viatris shares fell 2.6% to $17.04. JPMorgan stated: “We believe this acquisition will not significantly alter VTRS' overall financial profile in the short or long term, and expect Exparel’s sales to gradually decline post-2030 due to generic market entry.” Both parties expect to complete the transaction by the end of 2026. Including intraday fluctuations, PCRX shares have risen 40.2% year-to-date, while VTRS has gained 36.8%. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of automated translated texts and provides them for readers’ convenience only. Reuters assumes no liability for any damage or losses resulting from the use of automated translation.)

路透社•2026/10/08 16:11